Genelux Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $123.1M
- Price
- $2.72
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.73%
- Volume
- 223.7K
About
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Quick stats
Shares outstanding45.2M
Computed float38.2M
Float / shares84.5%
Cash runway (months)7.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001231457
Websitehttps://www.genelux.com
AI Summary
AI-generated1/5
minorneutralclinical trial
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Genelux reported Q2 net loss of $9.5 million, or $0.21 per share, with cash and equivalents of $18.7 million expected to fund operations into Q1 2027.
The company reaffirmed that topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer trial is anticipated in the second half of 2026.
R&D expenses increased to $6.5 million, driven by costs associated with the ongoing Phase 3 registrational trial.
Red flags
- Cash runway only extends into Q1 2027